Pfizer continuing talks with CDC about recommending Prevnar in adults over 50

Pfizer issued the following statement in response to today’s discussion by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices regarding the use of Prevnar 13 in adults 50 years of age and older: "Pfizer believes Prevnar 13 should be recommended for all adults 50 years of age and older given the current burden of pneumococcal disease in this age group...We are committed to continuing discussions with the CDC about a recommendation concerning the use of Prevnar 13 in adults 50 years of age and older...We are confident that Prevnar 13 has the potential to help address the burden of life-threatening pneumococcal pneumonia and invasive disease in adults 50 years of age and older, while offering a compelling value proposition for the United States health care system...Therefore, we intend to proceed with the launch of Prevnar 13 to health care providers in the United States in the coming weeks, as planned."